Logo image of CRMD

CORMEDIX INC (CRMD) Stock Fundamental Analysis

USA - NASDAQ:CRMD - US21900C3088 - Common Stock

10.075 USD
+0.09 (+0.95%)
Last: 11/18/2025, 8:00:01 PM
10.11 USD
+0.04 (+0.35%)
After Hours: 11/18/2025, 8:00:01 PM
Fundamental Rating

7

Taking everything into account, CRMD scores 7 out of 10 in our fundamental rating. CRMD was compared to 192 industry peers in the Pharmaceuticals industry. While CRMD has a great health rating, its profitability is only average at the moment. CRMD is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, CRMD could be worth investigating further for value and growth investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

CRMD had positive earnings in the past year.
In the past year CRMD had a positive cash flow from operations.
In the past 5 years CRMD always reported negative net income.
CRMD had a negative operating cash flow in each of the past 5 years.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With an excellent Return On Assets value of 20.25%, CRMD belongs to the best of the industry, outperforming 97.40% of the companies in the same industry.
With an excellent Return On Equity value of 23.19%, CRMD belongs to the best of the industry, outperforming 93.23% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 17.64%, CRMD belongs to the top of the industry, outperforming 94.79% of the companies in the same industry.
Industry RankSector Rank
ROA 20.25%
ROE 23.19%
ROIC 17.64%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin of CRMD (42.11%) is better than 98.44% of its industry peers.
The Operating Margin of CRMD (40.60%) is better than 97.40% of its industry peers.
CRMD has a Gross Margin of 95.62%. This is amongst the best in the industry. CRMD outperforms 96.35% of its industry peers.
CRMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 40.6%
PM (TTM) 42.11%
GM 95.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CRMD is creating value.
CRMD has more shares outstanding than it did 1 year ago.
CRMD has more shares outstanding than it did 5 years ago.
CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CRMD has an Altman-Z score of 14.61. This indicates that CRMD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CRMD (14.61) is better than 87.50% of its industry peers.
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 14.61
ROIC/WACC2
WACC8.81%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

CRMD has a Current Ratio of 7.82. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CRMD (7.82) is better than 76.04% of its industry peers.
A Quick Ratio of 7.52 indicates that CRMD has no problem at all paying its short term obligations.
CRMD's Quick ratio of 7.52 is fine compared to the rest of the industry. CRMD outperforms 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 7.82
Quick Ratio 7.52
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

CRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 354.32%, which is quite impressive.
The Revenue has been growing by 174.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)354.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2620%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%810.21%

3.2 Future

CRMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.07% yearly.
Based on estimates for the next years, CRMD will show a very strong growth in Revenue. The Revenue will grow by 65.91% on average per year.
EPS Next Y742.16%
EPS Next 2Y211.2%
EPS Next 3Y111.15%
EPS Next 5Y59.07%
Revenue Next Year617.18%
Revenue Next 2Y223.68%
Revenue Next 3Y117.61%
Revenue Next 5Y65.91%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 200M 400M 600M 800M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

10

4. Valuation

4.1 Price/Earnings Ratio

CRMD is valuated cheaply with a Price/Earnings ratio of 4.89.
Based on the Price/Earnings ratio, CRMD is valued cheaper than 96.35% of the companies in the same industry.
When comparing the Price/Earnings ratio of CRMD to the average of the S&P500 Index (25.51), we can say CRMD is valued rather cheaply.
With a Price/Forward Earnings ratio of 3.97, the valuation of CRMD can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 97.40% of the companies listed in the same industry.
CRMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.98, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 4.89
Fwd PE 3.97
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CRMD is valued cheaply inside the industry as 86.46% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, CRMD is valued cheaper than 81.25% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.73
EV/EBITDA 10.63
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CRMD has a very decent profitability rating, which may justify a higher PE ratio.
CRMD's earnings are expected to grow with 111.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y211.2%
EPS Next 3Y111.15%

More info and screens

0

5. Dividend

5.1 Amount

CRMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORMEDIX INC

NASDAQ:CRMD (11/18/2025, 8:00:01 PM)

After market: 10.11 +0.04 (+0.35%)

10.075

+0.09 (+0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-23 2026-03-23/amc
Inst Owners46.71%
Inst Owner Change22.5%
Ins Owners7.55%
Ins Owner Change14.86%
Market Cap752.10M
Revenue(TTM)43.47M
Net Income(TTM)51.16M
Analysts83.08
Price Target19.38 (92.36%)
Short Float %24.05%
Short Ratio5.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.96%
Min EPS beat(2)13.12%
Max EPS beat(2)58.8%
EPS beat(4)4
Avg EPS beat(4)44.57%
Min EPS beat(4)13.12%
Max EPS beat(4)58.8%
EPS beat(8)7
Avg EPS beat(8)23.17%
EPS beat(12)8
Avg EPS beat(12)15.69%
EPS beat(16)11
Avg EPS beat(16)13.24%
Revenue beat(2)2
Avg Revenue beat(2)9.08%
Min Revenue beat(2)3.69%
Max Revenue beat(2)14.48%
Revenue beat(4)4
Avg Revenue beat(4)9.28%
Min Revenue beat(4)3.62%
Max Revenue beat(4)15.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.23%
PT rev (3m)-1.21%
EPS NQ rev (1m)58.2%
EPS NQ rev (3m)191.37%
EPS NY rev (1m)30.88%
EPS NY rev (3m)105.99%
Revenue NQ rev (1m)31.07%
Revenue NQ rev (3m)116.37%
Revenue NY rev (1m)14.67%
Revenue NY rev (3m)75.65%
Valuation
Industry RankSector Rank
PE 4.89
Fwd PE 3.97
P/S 6.19
P/FCF 24.73
P/OCF 24.69
P/B 3.41
P/tB 3.44
EV/EBITDA 10.63
EPS(TTM)2.06
EY20.45%
EPS(NY)2.54
Fwd EY25.17%
FCF(TTM)0.41
FCFY4.04%
OCF(TTM)0.41
OCFY4.05%
SpS1.63
BVpS2.96
TBVpS2.93
PEG (NY)0.01
PEG (5Y)N/A
Graham Number11.7
Profitability
Industry RankSector Rank
ROA 20.25%
ROE 23.19%
ROCE 22.33%
ROIC 17.64%
ROICexc 129.11%
ROICexgc 137.01%
OM 40.6%
PM (TTM) 42.11%
GM 95.62%
FCFM 25.03%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score7
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 10.02%
Cap/Sales 0.04%
Interest Coverage 1343.8
Cash Conversion 61.11%
Profit Quality 59.44%
Current Ratio 7.82
Quick Ratio 7.52
Altman-Z 14.61
F-Score7
WACC8.81%
ROIC/WACC2
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)354.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2620%
EPS Next Y742.16%
EPS Next 2Y211.2%
EPS Next 3Y111.15%
EPS Next 5Y59.07%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%810.21%
Revenue Next Year617.18%
Revenue Next 2Y223.68%
Revenue Next 3Y117.61%
Revenue Next 5Y65.91%
EBIT growth 1Y184.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year651.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y197%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y197.89%
OCF growth 3YN/A
OCF growth 5YN/A

CORMEDIX INC / CRMD FAQ

What is the fundamental rating for CRMD stock?

ChartMill assigns a fundamental rating of 7 / 10 to CRMD.


What is the valuation status of CORMEDIX INC (CRMD) stock?

ChartMill assigns a valuation rating of 10 / 10 to CORMEDIX INC (CRMD). This can be considered as Undervalued.


Can you provide the profitability details for CORMEDIX INC?

CORMEDIX INC (CRMD) has a profitability rating of 6 / 10.


Can you provide the financial health for CRMD stock?

The financial health rating of CORMEDIX INC (CRMD) is 8 / 10.